KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EBIT: 2009-2024

Historic EBIT for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to -$248.9 million.

  • Novavax's EBIT fell 32.83% to -$178.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $307.5 million, marking a year-over-year increase of 202.01%. This contributed to the annual value of -$248.9 million for FY2024, which is 56.06% up from last year.
  • Novavax's EBIT amounted to -$248.9 million in FY2024, which was up 56.06% from -$566.5 million recorded in FY2023.
  • Over the past 5 years, Novavax's EBIT peaked at -$248.9 million during FY2024, and registered a low of -$1.7 billion during FY2021.
  • For the 3-year period, Novavax's EBIT averaged around -$486.7 million, with its median value being -$566.5 million (2023).
  • In the last 5 years, Novavax's EBIT slumped by 304.73% in 2021 and then surged by 61.77% in 2022.
  • Novavax's EBIT (Yearly) stood at -$416.7 million in 2020, then tumbled by 304.73% to -$1.7 billion in 2021, then spiked by 61.77% to -$644.7 million in 2022, then rose by 12.13% to -$566.5 million in 2023, then surged by 56.06% to -$248.9 million in 2024.